-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting LENSAR (NASDAQ:LNSR) & InspireMD (NYSE:NSPR)
Contrasting LENSAR (NASDAQ:LNSR) & InspireMD (NYSE:NSPR)
LENSAR (NASDAQ:LNSR – Get Rating) and InspireMD (NYSE:NSPR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Earnings and Valuation
This table compares LENSAR and InspireMD's revenue, earnings per share and valuation.
Get LENSAR alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENSAR | $34.46 million | 1.81 | -$19.60 million | ($2.40) | -2.36 |
| InspireMD | $4.49 million | 3.28 | -$14.92 million | ($2.22) | -0.80 |
InspireMD has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
56.0% of LENSAR shares are owned by institutional investors. Comparatively, 2.1% of InspireMD shares are owned by institutional investors. 19.0% of LENSAR shares are owned by insiders. Comparatively, 3.8% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.Analyst Ratings
This is a breakdown of current ratings and target prices for LENSAR and InspireMD, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 0 | 0 | 2 | 0 | 3.00 |
| InspireMD | 0 | 0 | 0 | 0 | N/A |
LENSAR currently has a consensus price target of $14.00, suggesting a potential upside of 147.35%. Given LENSAR's higher possible upside, equities research analysts clearly believe LENSAR is more favorable than InspireMD.
Risk and Volatility
LENSAR has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Profitability
This table compares LENSAR and InspireMD's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | -63.71% | -45.47% | -37.06% |
| InspireMD | -334.66% | -54.85% | -46.01% |
Summary
LENSAR beats InspireMD on 8 of the 13 factors compared between the two stocks.
About LENSAR
(Get Rating)
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
About InspireMD
(Get Rating)
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
LENSAR (NASDAQ:LNSR – Get Rating) and InspireMD (NYSE:NSPR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
納斯達克(Sequoia Capital：LNSR-GET Rating)和InspirreMD(NYSE：NSPR-GET Rating)都是小盤醫療公司，但哪種投資更好？我們將根據這兩家公司的收益、盈利能力、風險、分析師建議、股息、估值和機構所有權等方面的實力進行比較。
Earnings and Valuation
收益和估值
This table compares LENSAR and InspireMD's revenue, earnings per share and valuation.
該表格比較了LENSAR和InspirreMD的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENSAR | $34.46 million | 1.81 | -$19.60 million | ($2.40) | -2.36 |
| InspireMD | $4.49 million | 3.28 | -$14.92 million | ($2.22) | -0.80 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| LENSAR | 3,446萬美元 | 1.81 | -1,960萬元 | ($2.40) | -2.36 |
| InspirreMD | 449萬美元 | 3.28 | -1,492萬元 | ($2.22) | -0.80 |
InspireMD has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
InspirreMD的收入低於LENSAR，但收益高於LENSAR。LENSAR的市盈率低於InSpireMD，這表明它目前是兩隻股票中更負擔得起的一隻。
Institutional & Insider Ownership
機構與內部人持股
Analyst Ratings
分析師評級
This is a breakdown of current ratings and target prices for LENSAR and InspireMD, as provided by MarketBeat.
這是由MarketBeat提供的LENSAR和InspirreMD的當前評級和目標價格的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 0 | 0 | 2 | 0 | 3.00 |
| InspireMD | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| LENSAR | 0 | 0 | 2 | 0 | 3.00 |
| InspirreMD | 0 | 0 | 0 | 0 | 不適用 |
LENSAR currently has a consensus price target of $14.00, suggesting a potential upside of 147.35%. Given LENSAR's higher possible upside, equities research analysts clearly believe LENSAR is more favorable than InspireMD.
LENSAR目前的普遍目標價為14.00美元，暗示潛在上行147.35%。考慮到LENSAR較高的可能上行空間，股票研究分析師顯然認為LENSAR比InspirreMD更有利。
Risk and Volatility
風險和波動性
LENSAR has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
LENSAR的貝塔係數為-0.11，這意味着其股價的波動性比標準普爾500指數低111%。相比之下，InSpireMD的貝塔係數為1.27，這意味着其股價的波動性比標準普爾500指數高27%。
Profitability
盈利能力
This table compares LENSAR and InspireMD's net margins, return on equity and return on assets.
此表比較了LENSAR和InspirreMD的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | -63.71% | -45.47% | -37.06% |
| InspireMD | -334.66% | -54.85% | -46.01% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| LENSAR | -63.71% | -45.47% | -37.06% |
| InspirreMD | -334.66% | -54.85% | -46.01% |
Summary
摘要
LENSAR beats InspireMD on 8 of the 13 factors compared between the two stocks.
在比較兩隻股票的13個因素中，LENSAR在8個因素上擊敗了InspirreMD。
About LENSAR
關於LENSAR
(Get Rating)
(獲取評級)
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
LENSAR，Inc.是一家商業階段的醫療設備公司，專注於設計、開發和銷售一種飛秒激光系統，用於治療白內障和管理先前存在的或手術引起的角膜散光。其LENSAR激光系統結合了一系列專有技術，旨在通過提供成像、程序規劃、設計和精度來幫助外科醫生獲得可視結果、效率和重複性。該公司成立於2004年，總部設在佛羅裏達州奧蘭多。
About InspireMD
關於InspirreMD
(Get Rating)
(獲取評級)
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
InspirreMD公司是一家醫療設備公司，專注於開發專有的MicroNet支架平臺技術並將其商業化，用於治療歐洲、拉丁美洲、中東和亞太地區的血管和冠狀動脈疾病。該公司提供用於頸動脈應用的CGuard頸動脈血栓預防系統，以及用於急性冠脈綜合徵患者的MGuard Prime血栓保護系統，特別是急性心肌梗死、大隱靜脈移植冠狀動脈介入治療以及搭橋手術。它還在開發PVGuard，一種用於外周血管應用的MicroNet網狀套筒和自膨脹支架。該公司通過當地分銷商銷售其產品。InspirreMD，Inc.成立於2005年，總部設在以色列特拉維夫-亞福。
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
接受《LENSAR日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對LENSAR和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧